Adimab Revenue and Competitors
Estimated Revenue & Valuation
- Adimab's estimated annual revenue is currently $32.2M per year.
- Adimab received $25.0M in venture funding in April 2012.
- Adimab's estimated revenue per employee is $193,750
- Adimab's total funding is $45.5M.
- Adimab's current valuation is $1B. (February 2015)
Employee Data
- Adimab has 166 Employees.
- Adimab grew their employee count by 4% last year.
Adimab's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and CEO | Reveal Email/Phone |
2 | Chief Human Resources Officer | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | CFO | Reveal Email/Phone |
5 | VP Computational Biology | Reveal Email/Phone |
6 | VP Strategic Alliances | Reveal Email/Phone |
7 | Chief Scientific Officer | Reveal Email/Phone |
8 | Director | Reveal Email/Phone |
9 | Director | Reveal Email/Phone |
10 | Senior Director, Product Engineering and Operations | Reveal Email/Phone |
Adimab Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.7M | 61 | 20% | N/A | N/A |
What Is Adimab?
Adimab's yeast-based discovery platform functions as a synthetic human immune system to create novel antibody therapeutics across an extensive range of diseases, including cancer as well as autoimmune and infectious diseases. We are a profitable privately-held biotech company, backed by top-tier venture capital firms including Google Ventures, OrbiMed Advisors, Polaris Partners, and SV Life Sciences. We are unique in our ability to take a long-term view on value creation which allows us to continuously refine and improve our technology and make substantial investments in R&D.
keywords:Biotechnology
$45.5M
Total Funding
166
Number of Employees
$32.2M
Revenue (est)
4%
Employee Growth %
$1B
Valuation
N/A
Accelerator
Adimab News
Trisha Sackett worked on isolating antibodies at Adimab in Lebanon, N.H., in December. Waltham-based Adagio Therapeutics was spun out of...
OmniAb notes that both AbCellera and Adimab do not disclose if the programs or partnerships reflected in these totals are ongoing or terminated...
After burning through slightly more than $81 million, a biotech co-founded by Adimab’s Tillman Gerngross has pencilled in a $57.5 million raise from an IPO designed to get its mid-stage pneumonia fighting antibody through Phase II and down the road to a potential approval. Til ...
The technology was spun out from Dartmouth College in 2013, and is chaired by storied biotech businessman Tillman Gerngross of Adimab. The company uses affinity purification to develop what it says is a highly precise biologics manufacturing system – separating out impurities that were previous ...
Adimab, LLC, a Lebanon, NH-based company that discovers fully human antibodies, has closed an over-subscribed Series F financing of undisclosed amount. The additional funds were raised entirely from existing investors. The company intends to use the capital to pursue complementary opportunitie ...
Other Companies in Lebanon
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $63.4M | 167 | 1% | N/A |
#2 | $47.4M | 176 | -1% | N/A |
#3 | $54.1M | 182 | 5% | N/A |
#4 | $57.9M | 195 | 0% | N/A |
#5 | $38.8M | 196 | 0% | N/A |
Adimab Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-03-26 | $Undisclosed | B | Polaris Venture Partners, SV Life Sciences | Article |
| 2008-11-21 | $Undisclosed | C | OrbiMed Advisors, Borealis Ventures | Article |
| 2009-10-02 | $Undisclosed | D | Google Ventures | Article |
| 2012-04-04 | $25.0M | F | Polaris Venture Partners, Borealis Ventures | Article |